Summary: Oxyresveratrol (OXY) is a natural hydroxystilbene that shows similar bioactivity but better water solubility than resveratrol. This study aims to characterize its glucuronidation kinetics in human liver (HLMs) and intestinal (HIMs) microsomes and identify the main UDP-glucuronosyltransferase (UGT) isoforms involved. Three and four mono-glucuronides of OXY were generated in HIMs and HLMs, respectively, with oxyresveratrol-2-O-¢-D-glucuronosyl (G4) as the major metabolite in both organs. The kinetics of G4 formation fit a sigmoidal model in HLMs and biphasic kinetics in HIMs. Multiple UGT isoforms catalyzed G4 formation with the highest activity observed with UGT1A9 followed by UGT1A1. G4 formation by both isoforms followed substrate inhibition kinetics. Propofol (UGT1A9 inhibitor) effectively blocked G4 generation in HLMs (IC 50 63.7 « 11.6 µM), whereas the UGT1A1 inhibitor bilirubin only produced partial inhibition in HLMs and HIMs. These findings shed light on the metabolic mechanism of OXY and arouse awareness of drug interactions.
Introduction
Recently, oxyresveratrol (OXY, trans-2,3A,4,5A-tetrahydroxystilbene), as well as piceatannol (trans-3,3A,4,5A-tetrahyroxystilbene), has received more attention because of their high structural and biological similarity to resveratrol (trans-3,4A,5-tetrahyroxystilbene), the most important stilbene related to human health. [1] [2] [3] With an additional hydroxyl group on the resveratrol molecule ( Fig. 1) , OXY exhibited similar biological activities including radical scavenging, anti-oxidant, anti-inflammatory, anti-viral, and neuroprotective properties. [3] [4] [5] [6] Compared with resveratrol, OXY showed comparable inhibitory activity on African swine fever virus 3) and higher free radical scavenging activity. 6) This hydroxylated analog of resveratrol naturally exists in free form and/or its glycosides in Mori Cortex, the root bark of Morus alba L., as well as in mulberry fruit or fruits of several plants belonging to the Artoarpus genus. 7) It was reported that mulberroside A (MulA), one major constituent in the medicinal herb Mori Cortex, which is widely used to treat gout, arthritis and rheumatism in traditional Chinese medicine, was converted to OXY, and the latter was transported into the circulating blood and tissues at high rates in rats 8) and exhibited higher biological activity than MulA in both in vivo and in vitro studies. 9) Although there are many studies focusing on assessment of the pharmacological activity of OXY, its metabolism has not been adequately characterized. The presence of four hydroxyl groups on the stilbene core structure (Fig. 1A) makes OXY an ideal substrate for phase II biotransformation, and the mono-glucuronides and mono-sulfates of OXY were detected in rat urine or bile after oral administration of OXY. 10) Our previous in vitro study also revealed major glucuronidation and minor sulfation of OXY in liver microsomes of humans and rats.
11) It is interesting to note that, although all four positions can be glucuronidated, liver microsomal proteins showed an absolute positional preference which varied with species. The 2-glucuronosyl of OXY appeared as the predominant metabolite formed by human liver microsomes. Knowing the main UDP-glucuronosyltransferase (UGT) isoform(s) involved in the glucuronidation of OXY, especially those in the formation of the 2-glucuronosyl of OXY, will help predict potential drug interactions mediated by particular enzyme isoforms and polymorphism-related interindividual variability. However, so far, there is no such data to fill the knowledge gap. Glucuronidation represents both clearance and detoxification mechanisms for a large number of compounds that include drugs, nondrug xenobiotics and endogenous compounds. There are also accumulating data supporting a contribution of glucuronidation to beneficial actions of compounds by generating bioactive metabolites. Glucuronidation reactions are catalyzed by enzymes of the UGT superfamily. In humans, there are 19 known functional UGTs categorized into three subfamilies (1A, 2A and 2B) based on gene structure and sequence homology.
12) The individual UGT enzymes exhibit distinct, but overlapping, substrate and inhibitor selectivity and differ from each other in terms of gene regulation as well as tissue distribution. 13) UGTs are variably expressed in different tissues with liver as a principal site of UGT-mediated conjugation.
13) The intestine also plays an important role in the first-pass metabolism of drugs that are mainly metabolized by some UGTs.
14)
The aim of this study was to characterize the kinetics of OXY glucuronidation by liver and intestinal microsomes of humans and identify the main UGT isoforms involved using recombinant human UGTs and isoform-specific chemical inhibitors.
Materials and Methods
Materials: Oxyresveratrol (OXY) (purity > 98%) was supplied by Kuiqing Co., Ltd. (Tianjin, China). Bilirubin, propofol, uridine 5A-diphosphoglucuronic acid (UDPGA), MgCl 2 , alamethicin, Tris-HCl (pH 7.4) and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO). Methanol and formic acid of high-performance liquid chromatography (HPLC) grade were purchased from Merck (Darmstadt, Germany). Purified water was prepared using a Milli-Q water purification system from Millipore Corporation (Millipore, Bedford, MA). All chemicals and reagents were of the highest purity commercially available. OXY glucuronide (oxyresveratrol-2-O-¢-D-glucuronosyl: G4) was biosynthesized using pooled human liver microsomes, and separated and purified using a semi-preparative HPLC-DAD method.
11)
Pooled human liver microsomes (HLMs) and human intestinal microsomes (HIMs) were purchased from Research Institute for Liver Diseases (Shanghai) Co. Ltd. (Shanghai, China). Pooled HLMs were prepared from 11 Mongolian male donors aged from 24 to 35 years (28.1 « 5.0 years) and pooled HIMs were prepared from 10 donors with mixed gender aged from 7 to 83 years (46.7 « 24.1 years). Recombinant human UGTs (UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15 and 2B17) expressed by baculovirus-infected insect cells were purchased from BD Biosciences (Bedford, MA, USA) and their activities were confirmed with respective probe substrates by the manufacturer.
Metabolism of OXY by HLMs and HIMs: Glucuronidation activity of OXY was determined in pooled human liver microsomes (HLMs) and human intestinal microsomes (HIMs). Initial rate conditions with respect to time and microsomal protein concentration were optimized in preliminary studies. The stock solution of OXY was prepared in DMSO and protected from light. The incubation mixture contained 0.8 mg/mL of HLMs or HIMs, OXY (1-400 µM) in DMSO (DMSO¯1%, v/v), alamethicin (25 µg/mL) and MgCl 2 (8 mM) in Tris-HCl buffer (50 mM, pH 7.4) in a total volume of 200 µL. Reactions were preincubated at 37°C for 5 min and initiated by adding the cofactor UDPGA (2 mM). The reactions were kept at 37°C for 10 min before adding 100 µL ice-cold methanol. After centrifugation at 15,000 © g for 10 min at 4°C, the supernatants were subjected to HPLC-DAD or LC-MS/MS analysis. All incubations were carried out in triplicate. Zero-minute incubations and incubations without UDPGA or with denatured HLMs (heating at 100°C for 10 min) served as controls.
Metabolism of OXY by recombinant human UGT isoenzymes: Each recombinant human UGT (UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17) was incubated individually with OXY to screen for the UGT isoforms that catalyze G4 formation. The incubations were carried out following the guidelines from the manufacturer: OXY (10 and 50 µM) was incubated with 0.075 mg/mL of each individual UGT isoform for 10 min. All other conditions were the same as described above for glucuronidation of OXY by microsomal proteins. All reactions were conducted in triplicate.
Kinetic studies were further carried out for the top two UGTs (UGT1A9 and UGT1A1) that exhibited high activity towards G4 formation from OXY to estimate their contributions in OXY glucuronidation by human liver or intestine. The reaction conditions were the same as described above for UGT screening with OXY ranging from 1 µM to 400 µM. Reactions were terminated and samples were prepared in the same manner as those of HLMs and HIMs.
Effects of chemical inhibitors on OXY glucuronidation in HLMs and HIMs: The involvement of UGT1A9 and UGT1A1 in G4 formation from OXY glucuronidation by HLMs and HIMs was evaluated with propofol (UGT1A9 inhibitor) 15) and bilirubin (UGT1A1 inhibitor), 16) respectively. Microsomal proteins (HLMs or HIMs, 0.8 mg/mL) were preincubated with OXY (10 µM) in the presence of a series of concentrations (10, 25, 50 , 100, 250, 500 and 1,000 µM) of bilirubin or propofol at 37°C for 5 min; then the reaction was initiated by adding 2 mM of UDPGA and kept for 10 min. Reactions in the absence of the inhibitor served as controls (100%). Sample preparation was the same as described above. The IC 50 , the inhibitor concentration that results in 50% inhibition of the control activity, was determined by nonlinear curve fitting the metabolite formation velocity and inhibitor concentration data using GraphPad Prism 5.0 software (GraphPad Software Inc., San Diego, CA).
HPLC-DAD and LC-MS/MS analysis: To quantify the OXY glucuronides, a sensitive reverse phase HPLC assay was performed as described previously with minor modification.
The HPLC system (HP 1200 series; Agilent Technologies, Santa Clara, CA) consisted of a vacuum degasser, a binary pump, an autosampler, and a diode array detector (DAD). Analytes were eluted on an Alltech Alltima C18 column (250 mm © 4.6 mm, 5 µm) and monitored at the wavelength at 320 nm. The column temperature was 35°C. The mobile phase consisted of 0.1% formic acid in water (A) and methanol (B) and was eluted at 1 mL/min with a linear gradient increasing from 5% to 100% B within 38 min. The injection volume was 70 µL.
Metabolite identification was performed on an ABI 4000 QTrap™ hybrid triple quadrupole linear ion trap mass spectrometer (Applied Biosystems, Foster City, CA) equipped with a Turbo V ionization source and controlled with an Analyst 1.5 software (Applied Biosystems). The mass spectrometer was operated in negative ion mode with conditions set as follows: ion-spray voltage, ¹5,500 V; ion source temperature 500°C; nebulizer gas (gas1), nitrogen, 40 psi; turbo gas (gas2), nitrogen, 40 psi; curtain gas, nitrogen, 20. OXY glucuronides were monitored in multiple reaction monitoring (MRM) mode at the mass transition of m/z 419.0¼242.9.
Quantification of OXY glucuronides: As standards of the OXY glucuronides were not commercially available, the amount of each OXY glucuronide formed in vitro was calculated from the standard curve of the parent compound OXY with a UV conversion factor (K).
The calibration curve of OXY in the in vitro incubation system was constructed over 1-400 µM using the HPLC-UV method. Good linearity was observed for OXY over the tested concentration range (Y = 30.84X ¹ 9.032, R 2 = 0.999). The K value was determined according to previous reports with some modifications. 17, 18) Briefly, different concentrations of OXY (1-400 µM) were incubated with HLMs (0.8 mg/mL) in the presence of UDPGA at 37°C for 10 min before 100 µL of methanol was added. After centrifugation, the supernatants were analyzed by HPLC as described above. The peak area decrease of OXY (¦Peak area OXY) and the total peak area of the glucuronides formed [¦Peak area (G1+G2+G3+G4)] were obtained. The K value, the ratio of ¦Peak area (G1+G2+G3+G4) to ¦Peak area OXY [K = ¦Peak area (G1+G2+G3+G4)/¦Peak area OXY], was calculated to be 0.917.
Data analysis: All data were obtained from triplicate reactions and expressed as means « standard deviation (S.D.).
The kinetic type was judged from Eedie-Hofstee plots. 19 ) Kinetic parameters were obtained by fitting metabolite formation velocity and substrate concentration data to the appropriate kinetic models with the following equations, respectively, using GraphPad Prism 5.0 software (GraphPad Software Inc.).
Michaelis-Menten kinetics:
where v is the rate of metabolite formation, V max is the maximum metabolic velocity, K m is the Michaelis-Menten constant (substrate concentration at 50% V max ), and [S] is the substrate concentration. Biphasic kinetics:
where V max1 and K m1 represent the high-affinity component and V max2 and K m2 represent the low-affinity component. Substrate inhibition kinetics:
where K i is the substrate inhibition constant. Sigmoidal or autoactiviation kinetics:
where S 50 (analogous to K m ) is the substrate concentration resulting in 50% of V max , and n is the Hill coefficient describing the degree of sigmoidicity (n > 1).
In vitro intrinsic clearance (CL int,in vitro ) is defined as V max /K m .
Results
OXY glucuronidation by microsomes from human liver and intestine: When OXY was incubated with human liver microsomes in the presence of UDPGA, four additional peaks that eluted at 17.3 (G1), 17.9 (G2), 18.2 (G3) and 19.3 (G4) min, respectively, were observed in the HPLC-UV chromatograms ( Fig. 2A) . These peaks were not detected in control reactions, and thus were determined to be OXY metabolites. The mass spectra (Fig. 2B ) of these metabolites all exhibited the molecular ion at m/z 419 and the characteristic fragment ion at m/z 243, corresponding to a neutral loss of one glucuronic acid molecule (m/z 176). Therefore, G1, G2, G3 and G4 were all mono-glucuronides of OXY generated by HLMs. G4, the major metabolite as judged on basis of a much higher peak area than those of the other three, was previously identified to be oxyresveratrol-2-O-¢-D-glucuronosyl.
Incubation of OXY with HIMs, however, yielded only three metabolites. These metabolites exhibited the retention times and the mass spectra identical to those of G1, G2 and G4 generated by HLMs, respectively; thus they were tentatively assigned as G1, G2 and G4 (Fig. 2A) .
Compared to HIMs, HLMs showed a much higher activity toward OXY glucuronidation. The loss of the parent compound at 400 µM within 10 min was 18.5% in HLMs, yet 3.4% in HIMs, corresponding to the elimination rate of 9.24 « 1.09 and 1.71 « 1.07 nmol/min/mg protein, respectively. Among the four OXY glucuronides, G4, the C-2 glucuronide of OXY, was the major metabolite in both HLMs and HIMs. It accounted for 72.6% of the total glucuronides of OXY formed in HLMs and 63.8% of those in HIMs, followed by G2 (20.3%), G3 (5.7%) and G1 (1.2%) in HLMs, G1 (23.5%) and G2 (12.5%) in HIMs. When compared on the basis of peak area data obtained from HPLC-UV analysis, the amounts of G4, G2 and G1 formed in HLMs were approximate 4, 5, and one fifth times those generated in HIMs, respectively.
Kinetics of OXY glucuronidation in human liver and intestine microsomes: The kinetic profiles for the formation of OXY glucuronides in both HLMs and HIMs within a substrate concentration range of 1 to 400 µM were depicted in Figure 3 . The Eadie-Hofstee plots of G4 formed in HLMs and HIMs are shown in the insets of Figure 3 , and the corresponding enzyme kinetics parameters are summarized in Table 1 . In HLMs, the kinetics for G4 formation fit sigmoidal (Hill) kinetics with a Hill coefficient of 1.56 (Fig. 3A and Table 1 ), whereas the G1 and G3 formation fit Mechaelis-Menten kinetics. HLMs exhibited the highest activity [V max : 4.8 « 0.1 (G4) vs 0.11 « 0.01 (G1), 0.5 « 0.1 (G3) nmol/min/mg protein] but lowest affinity [K m : 170.6 « 53.2 (G4) vs 39.9 « 17.7 (G1), 12.1 « 3.8 (G3) µM] towards G4 formation. Both the affinity and the capacity of HLMs for G3 formation were higher than those for G1. The formation rates of G2 were almost linear up to the highest OXY concentration of 400 µM, indicating that the apparent K m value was >400 µM. Thus, K m and V max values of G2 formation by HLMs could not be calculated.
As shown in the inset of Figure 3B , the Eadie-Hofstee plot of G4 in HIMs showed a biphasic profile, suggesting that two components were involved in the formation of G4 in HIMs. Although the apparent maximum velocity for the low-affinity component (V max2 , 1.4 « 0.03 nmol/min/mg protein) was larger than that for the high-affinity component (V max1 , 0.3 « 0.1 nmol/min/mg protein), the intrinsic clearance of the low-affinity component and the high-affinity component was comparable (CL int1 , 24.4 µL/min/mg protein; CL int2 , 21.3 µL/min/mg protein). The kinetics for formation of G1 and G2 fit well to the typical kinetics mode. Both the V max (0.55 « 0.02 nmol/min/mg protein) and K m (81.3 « 9.4 µM) of G1 in HIMs were approximately double those of G2 (V max , 0.28 « 0.02 nmol/min/mg protein; K m , 46.3 « 8.0 µM); as a result, the intrinsic clearance of OXY via G1 (CL int , 6.8 µL/min/mg protein) was comparable to that via G2 (CL int , 6.1 µL/min/mg protein), and both were much lower than that via G4.
Glucuronidation of OXY by recombinant UGT isoforms: The enzymes involved in the formation of the major metabolite G4 in HLMs and HIMs were further characterized with twelve commercially available recombinant human UGT isoforms. As shown in Figure 4 , most isoforms except for UGT1A4, 2B4, 2B15 and 2B17 generated detectable G4. The glucuronidation activity of the human UGTs showed a similar descending order at two substrate concentrations tested (10 and 50 µM). Among them, UGT1A9 exhibited the highest activity, followed by UGT1A1. UGT1A3, 1A6, 1A7, 1A8, 1A10 and 2B7 catalyzed G4 formation from OXY at much lower activities. In addition to G4, UGT1A9 and UGT1A1 also catalyzed G2 formation at much lower activities (data not shown). UGT1A1 could also convert OXY to minor G1. Neither UGT1A9 nor UGT1A1 could catalyze OXY to form G3 (data not shown).
The kinetic profiles for the formation of G4 in UGT1A9 and UGT1A1 are shown in Figures 3C and 3D , and corresponding enzyme kinetic parameters are summarized in Table 1 . In both cases, the Eadie-Hofstee plots for G4 formation exhibited a hook in the upper quadrant (insets of Fig. 3) , indicating a substrate inhibition kinetics. The maximal velocity of G4 formation was 30.3 « 2.4 nmol/min/mg protein in UGT1A9, 16-and 6-fold greater than that in UGT1A1 (1.8 « 0.1 nmol/min/mg protein) and HLMs (4.8 « 0.1 nmol/min/mg protein), respectively. A direct comparison could not be made with HIMs in which G4 formation followed a biphasic kinetic mode. Compared with UGT1A9, UGT1A1 showed a higher affinity (K m , UGT1A1 1.5 « 0.5 µM vs UGT1A9 7.4 « 1.3 µM) but a much lower activity toward G4 formation. The K i estimates for G4 formation were markedly different in UGT1A1 versus UGT1A9 (K i , 349.5 « 112.8 µM in UGT1A1 vs 167.2 « 31.8 µM in UGT1A9).
Inhibition of G4 formation in HLMs and HIMs by UGT inhibitors: To further confirm the involvement and estimate the contributions of UGT1A9 and UGT1A1 in hepatic and intestinal glucuronidation of OXY, the inhibitory effects of propofol (inhibitor of UGT 1A9) and/or bilirubin (inhibitor of UGT1A1) on G4 formation in HLMs and HIMs were examined. As shown in Figure 5 , propofol showed a potent inhibitory effect on OXY glucuronidation in HLMs and suppressed G4 formation in a concentration-dependent manner with the IC 50 value of 63.7 « 11.6 µM. The formation of G4 by HLMs was almost blocked in presence of 1,000 µM of propofol. In contrast, bilirubin only showed a weak effect and produced the maximum inhibition of 37% on G4 formation in HLMs at 500 µM. The inhibitory effect of bilirubin on OXY glucuronidation in HIMs was also weak, and it only suppressed G4 formation by 25% even at the highest concentration.
Discussion
Recently, glucuronide conjugates of some drugs have been reported to possess significant pharmacological activities, 22, 23) implying the impact of the glucuronidation process in therapeutic outcomes of these drugs. As one of the naturally existing hydroxystilbenes, OXY has exhibited various beneficial activities and very good solubility, yet received much less attention than its analog resveratrol. Previous studies revealed the phase II conjugates, especially the glucuronides, of OXY as its main existing forms in vivo, 11) indicating the impact of conjugation on healthpromoting effects of this compound. Our previous study reported extensive glucuronidation of OXY in liver microsomes from humans and rats, and revealed a great species difference in positional preference of hepatic glucuronidation of OXY. In the present study, the contribution of the liver and intestine on elimination of OXY via glucuronidation in human body was estimated from the glucuronidation of OXY by microsomal proteins. Moreover, the main UGTs involved in formation of the major metabolite oxyresveratrol-2-O-¢-D-glucuronosyl (G4) from OXY were identified for the first time.
Both HLMs and HIMs catalyzed OXY glucuronidation with the former showing a much higher activity. It is interesting to note that both trans-and cis-resveratrol showed higher glucuronidation in HIMs than HLMs. 20, 24) This difference in glucuronidation activity between the polyhydroxystilbene analogs could result from the structural difference. A further study comparing glucuronidation of resveratrol and oxyresveratrol by the same HIMs and HLMs samples is warranted to rule out the differences caused by different microsomal protein samples used.
Our previous study revealed a distinct positional preference of glucuronidation of OXY between species, with G3 as the major in rat liver and G4 as the major in human liver. 11) While, in the present study, the same positional preference of OXY glucuronidation at the C-2 position (G4) was observed in the liver and intestine of humans. This finding together with our previous report arouses awareness of species difference when the efficacy/ toxicity data of the polyhydroxystilbenes obtained from rats were extropolated to humans. The positional preference of glucuronidation was also observed with OXY analogs. Resveratrol was metabolized to two glucuronides by HLMs and HIMs, with resveratrol-3-O-glucuronide as the major and resveratrol-4A-Oglucuronide as the minor. 20, 25) HLMs converted piceatannol to three glucuronides (M1, M2 and M3), among which M3 was the major metabolite. 26) However, the exact preferential position of glucuronidation of piceatannol is unknown, making it difficult to compare the regioselectivity in glucuronidation of the two tetrahydroxystilbenes by human livers. There was also regioselective difference in OXY glucuronidation by different organs from humans as judged on basis of the number of mono-glucuronides (four in HLMs and three in HIMs) generated as well as the relative abundance of each metabolite (the descending order of abundance: G4, G2, G3 and G1 in liver; G4, G1 and G2 in intestine). The formation rate of G1 was even higher in HIMs than that in HLMs. Many factors, such as the position of the OH group, nucleophilicity and steric characteristics, have been reported to affect the overall efficacy and the positional preference of the glucuronidation of polyphenolic compounds, among which flavonoids have been well characterized. 17) These factors could account for the preferential glucuronidation of the hydroxystilbenes observed in the present and previous studies.
The intrinsic clearance of oxyresveratrol via G4 by HLMs and HIMs obtained from this study was comparable to those reported for the major glucuronides of resveratrol and piceatannol. by HIMs were very close to that reported for resveratrol (24.1 µL/min/mg protein). These findings suggest a high similarity in first-pass elimination of these hydroxystilbene analogs in human beings. G4 formation from OXY followed sigmoidal kinetics in HLMs but fit a biphasic model in HIMs, indicating involvement of different enzymes in OXY glucuronidation by the two organs. The kinetic profiles of OXY glucuronidation were different from those of resveratrol and piceatannol. 20, 26) The formation of the major resveratrol-3-O-glucuronide from resveratrol in both HLMs and HIMs fit the substrate inhibition model, whereas that for the minor 4A-O-glucuronide of resveratrol exhibited a biphasic kinetic profile in HLMs and substrate inhibition in HIMs. The formation of the major glucuronide (M3) of piceatannol in HLMs also exhibited a substrate inhibition profile. In these previous studies from other groups, the enzyme kinetics was characterized at much higher substrate concentrations (up to 5,000 and 2,000 µM for resveratrol and piceatannol, respectively) than the OXY concentrations used in this study, making it difficult to compare the kinetic profiles of these hydroxystilbene analogs directly.
Among all tested recombinant human UGT isoforms, UGT1A9 showed the highest glucuronidation activity towards OXY as judged on basis of G4 formation. UGT1A9 is abundant in human liver, 27) but very little occurs in the intestine. 27, 28) Furthermore, the UGT1A9 inhibitor propofol was able to completely inhibit the formation of the major metabolite G4 from OXY in HLMs. Taken together, these findings support that UGT1A9 is the main UGT isoform mediating the glucuronidation of OXY in the human liver.
UGT1A1 also showed relatively higher activity toward G4 formation. Although UGT1A1 is highly expressed in both the liver and intestine, 28) its contribution on the formation of G4 in HLMs is likely to be minor since the UGT1A1 inhibitor bilirubin only partially blocked OXY glucuronidation in HLMs. Among the UGT isoforms expressed in the intestine (UGT1A1, 1A3, 1A5, 1A6, 1A7, 1A8, 1A9, 1A10, 2B7, 2B15 and 2B17), 28) UGT1A1 showed the highest glucuronidation activity towards G4 formation. Moreover, similar to HIMs, UGT1A1 also catalyzed formations of G1, G2 and G4, but not G3. The ratio of G1 to G4 generated by UGT1A1 and HIMs was also comparable (0.40 vs 0.37) (data not shown). Thus, it is reasonable to speculate that UGT1A1 is the main UGT isoform catalyzing the G4 formation from OXY in HIMs. However, the UGT1A1 inhibitor bilirubin only produced ³25% of inhibition towards G4 formation by HIMs, suggesting the involvement of other UGT isoforms in OXY glucuronidation in HIMs.
Recent studies revealed that UGT1A7, UGT1A8 and UGT1A10 are extremely low or not detectable in the human liver, but exclusively expressed in the gastrointestinal tract. 28, 29) Among the UGT1A isoforms expressed in the human intestine, the expression level of UGT1A10 was the highest, followed by UGT1A1. The expression levels of UGT1A3, 1A6, 1A7 and 1A8 were less than one tenth that of UGT1A10. 28, 30) The UGT2B family isoform 2B7 was also detected at high levels in both human liver and small intestine. These aforementioned isoforms all catalyzed G4 formation from OXY although at lower activities. Thus, OXY glucuronidation in the human intestine is likely to be catalyzed by multiple UGT isoforms. This speculation was supported by the biphasic kinetics of G4 formation observed in HIMs.
Similar to OXY glucuronidation, UGT1A1 and UGT1A9 were also reported to be the main isoforms catalyzing resveratrol glucuronidation with UGT1A9 showing a higher activity than UGT1A1. 20, 31) It is interesting to note that the glucuronidation of piceatannol, which is also a tetrahydroxystilbene like OXY, was mainly catalyzed by UGT1A1 in HLMs. The differences found for these analogs might be due to different binding affinities of individual UGT isoforms to an ortho or a para OH group and warrant further study. The kinetic profiles of OXY in UGT1A isoforms followed substrate inhibition kinetics, which were also reported for other stilbenes. The formations of these stilbene glucuronides were described by a two-site model in which one binding site was productive, whereas the other site was inhibitory and operable at high concentrations, resulting in decreased velocity with increasing substrate concentration. 20, 24) In conclusion, OXY is extensively glucuronidated with preference at the C-2 position in both the liver and intestine of humans. The formation of the major metabolite G4 followed sigmoidal kinetics in HLMs while it exhibited a biphasic profile in HIMs. Extensive first-pass glucuronidation of OXY is expected in both the human liver and intestine. UGT1A9 was demonstrated to be the main isoform mediating OXY glucuronidation in HLMs, while multiple UGT isoforms including UGT1A1, 1A3, 1A6, 1A7, 1A8, 1A10 and 2B7 mediate OXY glucuronidation in HIMs.
